Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO)
- First Online:
- Cite this article as:
- Penack, O., Becker, C., Buchheidt, D. et al. Ann Hematol (2014) 93: 1083. doi:10.1007/s00277-014-2086-0
- 3.4k Views
Sepsis is a major cause of mortality during the neutropenic phase after intensive cytotoxic therapies for malignancies. Improved management of sepsis during neutropenia may reduce the mortality of cancer therapies. Clinical guidelines on sepsis treatment have been published by others. However, optimal management may differ between neutropenic and non-neutropenic patients. Our aim is to give evidence-based recommendations for haematologist, oncologists and intensive care physicians on how to manage adult patients with neutropenia and sepsis.
Clinical significance and methods
Sepsis is a leading cause of mortality in patients with haematologic malignancies or solid tumours undergoing intensive cytotoxic chemotherapy [29, 168]. Therefore, optimization of diagnosis and management of sepsis could improve outcome of intensive cytotoxic therapies. A number of prior guidelines on the management of sepsis have been published [15, 41, 43, 60, 96, 106, 132, 137]; however, none of these guidelines specifically address diagnosis and management of sepsis in neutropenic patients.
Categories of evidence used in this guideline 
Strength of recommendation
Good evidence to support a recommendation for use
Moderate evidence to support a recommendation for use
Poor evidence to support a recommendation
Moderate evidence to support a recommendation against use
Good evidence to support a recommendation against use
Quality of evidence
Evidence from ≥1 properly randomized, controlled trial
Evidence from ≥1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from >1 centre); from multiple time-series; or from dramatic results from uncontrolled experiments
Evidence from opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees
A formal definition of sepsis has long been tried by several researchers and must lack specificity given the broad spectrum of reactions to pathogens.
Fever (core temperature >38.3 °C)
Hypothermia (core temperature <36.0 °C)
Heart rate (>90 bpm or >2 SD above the normal value for age)
Tachypnoea (>30 bpm)
Altered mental status
Significant edema or positive fluid balance (>20 mL/kg over 24 h)
Hyperglycaemia (plasma glucose >110 mg/dL or >7.7 mmol/L) in the absence of diabetes
Plasma C reactive protein or plasma procalcitonin (>2 SD above the normal value)
Arterial hypotension (systolic blood pressure <90 mmHg, mean arterial pressure <70 mmHg, or a systolic blood pressure decrease >40 mmHg in or <2 SD below normal for age)
Mixed venous oxygen saturation (>70 %)
Cardiac index (>3.5 L/min/m2)
Organ dysfunction parameters
Arterial hypoxaemia (PaO2/FIO2 <300)
Acute oliguria (urine output <0.5 mL/kg/h for ≥2 h)
Creatinine increase (≥0.5 mg/dL)
Coagulation abnormalities (international normalized ratio >1.5 or activated partial thromboplastin time >60 s)
Ileus (absent bowel sounds)
Hyperbilirubinemia (plasma total bilirubin >4 mg/dL or 70 mmol/L)
Tissue perfusion parameters
Hyperlactataemia (>3 mmol/L)
Decreased capillary refill or mottling
Definitions of severe sepsis and septic shock
Sepsis with new signs of organ dysfunction or a decrease in organ perfusion (lactate acidosis, oliguria (<30 mL/h or <0.5 mL/kg/h), hypotension (<90 mmHg or decrease of >40 mmHg), mental alteration)
Severe sepsis and hypotension persistent despite adequate fluid substitution and exclusion for other reasons for hypotension
Systematic data evaluating the overall incidence of neutropenic sepsis in cancer patients are lacking. The incidence of febrile neutropenia and bacteraemia has been studied more in detail, albeit the majority of studies did not use uniform definitions, include at least partly non-neutropenic patients and focus on distinct patient subgroups. Patients with solid tumours develop febrile neutropenia in around 10–40 %, but this complication might occur in more than 80 % of patients with haematological malignancies [1, 54]. In patients with indwelling central venous catheters (CVC), febrile neutropenia is frequently caused by catheter-related or catheter-associated bacteraemia with an incidence of around 10–20/1,000 neutropenic days [16, 34]. Likewise, translocation of gut organisms, such as vancomycin-resistant enterococci (VRE), may cause bacteraemia and, ultimately, sepsis in neutropenic cancer patients in up to 40 % of colonized patients [30, 101, 154].
It can be assumed that >50 % of patients with febrile neutropenia or bacteraemia develop sepsis using the consensus definition. Severe sepsis and septic shock, which have been investigated in a few prospective and retrospective analyses, might occur in up to 20–30 and 5–10 % of patients with febrile neutropenia, respectively [6, 78, 81, 95, 109, 112].
The increasing numbers of elderly patients undergoing intensive treatment modalities and patients infected with treatment-resistant organisms led to the assumption that the frequency of neutropenic sepsis will increase .
Risk factors and prognosis
Risk factors for bacteraemia
There are few data on risk factors for bacteraemia during neutropenia. Apostolopoulou et al. observed a significant higher rate of bacteraemia, potentially resulting in sepsis, in patients with neutropenia <0.5 g/L. Additionally, acute myeloid leukaemia, a prolonged hospital stay, a Hickman catheter, or pre-treatment with antibiotics, chemotherapy or surgery were significantly associated with BSI in haematological and oncological patients .
Risk factors for development of severe sepsis
The presence of hypophosphataemia (<0.8 mmol/L) and hypoproteinaemia (<62 g/L) have been identified as risk factors for severe sepsis in febrile neutropenia . The development of septic shock in febrile neutropenia is independently predicted by the presence of pulmonary infection, tachypnoea, increased serum levels of procalcitonin (≥1.5 ng/mL), high lactate levels [6, 109], decreased serum levels of bicarbonate (<17 mmol/L), antithrombin (<70 %) or factor VIIa (<0.8 ng/mL) [63, 78, 109, 135]. A low Multinational Association for Supportive Care in Cancer (MASCC) risk index score of <21 is associated with an increased risk for septic shock in febrile neutropenic patients .
Prolonged neutropenia <0.5 g/L or the delayed initiation of antibiotics is associated with poor clinical outcome in neutropenic patients with sepsis [5, 103]. Severe sepsis and septic shock negatively influence outcome [64, 95, 162]. A recent prospective study demonstrated mortality rates of 35 % in severe sepsis, 47 % in septic shock and 85 % in multi-organ failure in patients with haematological malignancies . Factors that were significantly associated with hospital survival included remission of malignant tumour and time to intensive care unit (ICU) admission <24 h. Negative predictive factors for hospital survival were as follows: allogeneic haemopoietic stem cell transplantation (HSCT), poor performance status, invasive pulmonary aspergillosis, malignant organ infiltration and acute respiratory failure. In another study, Legrand et al. identified prognostic factors for neutropenic patients with severe sepsis or septic shock: The appearance of acute non-infectious complications, of neurological, respiratory or hepatic dysfunction, the need for vasopressor therapy, or older age increased the mortality. On the other hand, the early removal of a CVC and combined antibiotic therapy were associated with higher survival .
Blood cultures as part of the usual microbiological work-up as per local protocol (including urine cultures, stool cultures etc.) remain the gold standard for the diagnosis of bacteraemia and fungaemia. Blood cultures should be standardized in terms of volume, culture sets, frequency, processing, interpretation and reporting.
Typical pathogens during bacterial sepsis in neutropenic patients
Coagulase-negative Staphylococci, Escherichia coli, Enterococcus species
Pseudomonas aeruginosa, Streptococcus pneumoniae (pneumococci), Viridans (alpha-haemolytic) streptococci, Acinetobacter species
Escherichia coli, P. aeruginosa, Clostridium spp., Enterococcus spp., Klebsiella species
Escherichia coli, Klebsiella species, Pseudomonas aeruginosa
Staphylococcus aureus, alpha-haemolytic streptococci
Coagulase-negative Staphylococci, Coryneform bacteria, Propionibacterium species, Candida albicans, Candida tropicalis, Candida parapsilosis, Stenotrophomonas maltophilia
The epidemiology of gram-positive versus gram-negative bacteraemia varies in different countries . In contrast to other countries, Germany has a predominance (>50 %) of gram-positive bacteria as the cause for febrile neutropenia . Knowledge about the local epidemiology is essential for a rational choice of empirical antibiotic therapy as already pointed out by others. This is particularly true for colonization with resistant bacteria, since these have been associated with an increased risk of bacteraemia with these pathogens .
PCR-based methods to detect bacterial and fungal DNA have yet to be validated in larger cohorts [8, 93, 105, 120, 164]. In contrast, PCR-based methods play a definitive role in the diagnosis of viral infections, which may cause sepsis in severely immunocompromised patients [71, 102, 129].
Empirical antimicrobial treatment using broad-spectrum antibiotics must be started immediately in neutropenic patients with sepsis (AII). A large retrospective study including more than 2,000 patients showed that during severe sepsis, effective antimicrobial administration within the first hour of documented hypotension is associated with increased survival . In this study, each hour of delay in antimicrobial administration over the ensuing 6 h was associated with an average decrease in survival of 7.6 % .
In neutropenic patients with sepsis, results from randomized controlled trials are lacking, and recommendations are based on study results from non-neutropenic patients as well as on expert opinions. We recommend initial treatment with meropenem or with imipenem/cilastatin or with piperacillin/tazobactam (AIII).
Meta-analyses show that a combination treatment with aminoglycosides increased renal toxicity without improving efficacy in neutropenic patients with bacteraemia [125–127]. However, in a retrospective study, the use of β-lactam antibiotic/aminoglycoside combinations were associated with superior outcome, as compared with single-agent antimicrobial treatment, in neutropenic patients with severe sepsis and septic shock . Another retrospective study showed reduced hospital mortality in non-neutropenic patients with severe bacterial sepsis after combination therapy comprising at least two antibiotics of different mechanisms versus antibiotic monotherapy . Taken together, a combination treatment with an aminoglycoside may be considered in neutropenic patients with septic shock and severe sepsis (BIII).
Knowledge of local microbiology data is crucial for the choice of antimicrobial agents. Importantly, local resistance patterns as well as colonization with resistant bacteria have to be considered . If infection due to bacteria with frequent resistance to carbapenems or piperacillin/tazobactam is suspected, a specific antibiotic should be added (BIII). If a specific organ infection is suspected, antibiotic therapy should be adapted accordingly. Recommendations on antifungal therapy during neutropenia were recently published by our group and by others [55, 104, 118, 157].
Treatment of cardiovascular insufficiency
Aggressive and early goal-directed treatment aiming at restoration of cardiovascular function is crucial [42, 140]. To restore adequate cardiac filling pressures and to maintain adequate organ perfusion (goal, mean arterial pressure 65 mmHg, central venous pressure 8–12 mmHg, pulmonary wedge pressure 12–15 mmHg, urinary output 0.5 mL/kg/h and central venous or mixed venous oxygen saturation 70 %), crystalloid fluids are recommended as the initial fluid of choice in severe sepsis and septic shock. Compared to crystalloids, randomized controlled trials did not show beneficial effects of colloids, especially hydroxyethyl starches for fluid resuscitation in sepsis [32, 62, 128]. However, the risk of acute kidney injury requiring renal replacement therapy is substantially increased by the use of hydroxyethyl starch (EI) .
While a large randomized study indicated that albumin administration was safe and equally effective as 0.9 % saline , a meta-analysis of data from 17 randomized trials found that the use of albumin-containing solutions for fluid resuscitation of patients with sepsis was associated with lower mortality compared with crystalloids . However, in a multicenter randomized trial (n = 794) in patients with septic shock, the use of albumin therapy did not significantly reduce 28-day mortality compared to saline solution . Thus, albumin-containing solutions may be used for fluid resuscitation of patients with sepsis and septic shock (CII).
If a sufficient mean arterial pressure (>65 mmHg) cannot be achieved by volume substitution in a reasonable time frame, treatment with vasopressors is indicated. The drug of choice to elevate the vasotonus is norepinephrine in a dose of 0.1–1.3 μg/kg/min (BII) .
In retrospective and small prospective studies, vasopressin (0.01–0.04 U/min) increased urinary output and creatinine clearance compared to norepinephrine [51–53]. However, in the large VASST trial, no reduction in 28-day mortality was found in the vasopressin group, and there is currently poor evidence to support the use of vasopressin in septic shock (CI) . In case of sepsis-related myocardial depression leading to low cardiac output despite adequate volume substitution, vasopressor treatment with dobutamine should be instituted (AII) . Of note, results from an observational study suggest that dopamine administration may be associated with increased mortality rates in septic patients .
Treatment of pulmonary failure
Pneumonia leading to acute respiratory failure is a major cause of sepsis in neutropenic cancer patients [19, 20]. On the other hand, severe sepsis may lead to acute lung injury/acute respiratory distress syndrome (ARDS) .
In cooperative and awake patients with mild to moderate pulmonary failure, non-invasive positive pressure ventilation should be preferred (AII) [19, 37, 69, 70, 145]. Both non-invasive treatment options led to a significant reduction of intubation compared to the control group in neutropenic cancer patients [19, 73]. An early start of non-invasive ventilation, prior to development of severe hypoxaemia, is favourable (BII) . Failure of non-invasive ventilation occurs in half of the critically ill haematologic patients and is associated with an increased mortality . Predictors of non-invasive ventilation failure are as follows: high respiratory rate, short time between admission and non-invasive ventilation , vasopressor use, renal replacement therapy and the development of ARDS .
In moderate to severe respiratory insufficiency, endotracheal intubation and mechanical ventilation are necessary. Survival is positively correlated to the experience of the ICU with haematologic and oncologic patients . In a retrospective multicenter study of allogeneic HSCT recipients admitted to the ICU, mechanical ventilation was associated with low survival rates . These data were confirmed in a prospective study .
Percutaneous extracorporeal membrane oxygenation showed to be a rescue therapy to bridge hypoxemia due to ARDS in patients with oncological or malignant haematological diseases [59, 99, 111]. Further studies are needed in this field, before a recommendation can be given.
Management of renal dysfunction
Acute kidney injury (AKI) develops in approximately 20 % of patients with severe sepsis and 50 % with septic shock. The combination of acute renal failure and sepsis is associated with a 70 % mortality . Specific data for neutropenic patients are lacking, and recommended management of renal dysfunction is not different from non-neutropenic patients.
In short, no clear guidelines on the timing of the initiation of renal replacement therapy (RRT) can be given. Regarding the mode of replacement therapy, intermittent haemodialysis and continuous renal replacement therapies (CRRT) are equivalent in patients with sepsis and AKI (BI) [57, 58, 84, 100, 134, 155]. In haemodynamically unstable patients, control of fluid balance may be facilitated by the use of CRRT (BII) [42, 79].
Increasing the frequency of RRT is thought to reduce the rate of uremic complications and improve outcome in patients with AKI. However, randomized controlled studies showed conflicting results [42, 79, 138]. A recent meta-analysis indicates that high-dose RRT in critically ill patients with AKI does not improve patient survival or recovery of renal function as compared with less-intensive regimes [75, 122, 160]. Thus, no firm recommendations can be given for the increased frequency of RRT (CI).
In patients undergoing renal replacement therapy, the dosage of antimicrobial substances should be carefully checked and adjusted . The use of low-dose dopamine for protection of renal function is not recommended (EI) [26, 85].
Nutrition and control of metabolic functions
Most recommendations reported are extrapolated from analyses in critically ill and well-nourished patients without neutropenia. Enteral nutrition is preferred over parenteral nutrition unless contraindicated or impossible, as it is associated with a lower rate of infections (BII) . Enteral caloric intake should be calculated according to the phase of sepsis: during the initial phase of sepsis, the supply of >20–25 kcal/kg ideal bodyweight (IBW) has been associated with inferior outcome in one observational study (DIII) . During recovery, 25–30 kcal/kg IBW should be provided (BIII) [89, 149].
As reproducible mortality benefits for supplementation of arginine [31, 56], omega-3 fatty acids [24, 130, 131] and combined formulations [27, 56, 68] in patients with severe sepsis and septic shock are lacking, we do not recommend general use of either of these supplements (DII). Substitution of glutamine did not positively affect the primary survival endpoint in two randomized trials including together over 1,000 patients with sepsis [9, 66] and significantly increased in-hospital and 6-month mortality in the REDOXS study . Therefore, glutamine substitution cannot be recommended (EI).
Two recent large randomized two-factorial trials compared the influence of lower doses of selenium substitution to placebo in critically ill patients [9, 66]. In these trials including 282 and 826 septic patients, respectively, selenium substitution had no effect on mortality [9, 66]. In a smaller trial, higher dose selenium substitution (1,000 μg daily) was associated with mortality reduction only in the per protocol analysis . In a meta-analysis including nine trials with septic patients, selenium substitution was associated with lower mortality, especially in patients receiving selenium in higher doses (≥1,000 mg daily) and for ≥6 days . Thus, further clinical trials regarding the adequate dosing and treatment duration are needed before treatment with selenium can be recommended (DI).
Hyperglycaemia in patients requiring intensive care is associated with an inferior outcome [23, 47]. Results of clinical trials in patients with severe sepsis and septic shock [13, 32] as well as clinical trials [51, 133, 158] including patients with underlying malignant disease  and a meta-analysis  in mixed populations of critically ill patients failed to show a benefit of intensified insulin therapy. These results are in contrast to the results of the initial trial by van den Berghe et al.  which had suggested a benefit of a tight blood glucose control (blood glucose level of 4.4–6.6 mmol/L (80–120 mg/dL)). Thus, we do not recommend intensive insulin therapy aiming at a blood glucose level of 4.4–6.6 mmol/L (80–120 mg/dL; EI). Based on these data and international guidelines [44, 76, 137], we recommend to maintain blood glucose levels at least ≤9.9 mmol/L (≤180 mg/dL; BIII). A high variability of blood glucose levels in septic patients should be avoided, as this is associated with increased mortality (BIII) [7, 22, 46].
Treatment with corticosteroids
Replacement of an impaired adrenal reserve and anti-inflammatory properties is a rationale for studying corticosteroids as an adjunctive to sepsis therapy. The use of corticosteroids in sepsis has not been studied in a prospective fashion for neutropenic patients. In the CORTICUS trial, 84 cancer patients were included; however, no subgroup analysis of these patients has been published .
High-dose corticosteroid treatment (>300 mg hydrocortisone per day)
Randomized controlled trials and meta-analyses reported on increased overall mortality and increased mortality from secondary infections in non-neutropenic patients with sepsis receiving high-dose steroids [28, 39, 113, 153, 163]. Thus, high-dose corticosteroids are not recommended as treatment of sepsis (EI).
Low-dose corticosteroid treatment (≤300 mg hydrocortisone per day)
Substitutive doses of hydrocortisone during sepsis remain controversial. Annane et al. identified a benefit in 28-day mortality for the treatment group . The CORTICUS trial did not reveal a difference in 28-day mortality between treatment and placebo and found a higher incidence of hyperglycaemia, hypernatraemia and secondary infections in the treatment group . The results of meta-analyses have been similarly contradictory. Some meta-analyses support the use of low doses of hydrocortisone [12, 114, 150], while others do not support the use of low doses of hydrocortisone [80, 116, 146]. Newer data from three observational studies with a total of over 25,000 patients from sepsis registries showed no mortality benefit for low-doses steroids [25, 33, 49]. Thus, we do not recommend the routine use of substitutive doses of hydrocortisone in neutropenic patients with sepsis (DI). However, low-dose corticoid treatment may be considered in patients with insufficient restoration of blood pressure levels despite adequate fluid resuscitation and vasopressor treatment (BII) . The results of three ongoing large randomized controlled trials will hopefully further clarify the role of low-dose steroids in severe sepsis.
Treatment with coagulation inhibitors
In sepsis, the coagulation cascade is frequently activated at early time points. As thrombocytopenia and an increased risk of bleeding are frequently present in patients with cancer and chemotherapy, attempts to positively influence coagulation in patients with neutropenia have to be exerted carefully.
Retrospective trials in patients with sepsis have shown a reduction in mortality using unfractionated heparin . The prospective randomized controlled HETRASE study has investigated treatment with low-dose heparin (500 IU/h during 7 days) in 319 patients with sepsis . No influence on 28-day all-cause mortality was found. This trial was characterized by low mortality, perhaps explained by liberal inclusion criteria. Treatment was discontinued when the partial thromboplastin time exceeded 60 s. Under these conditions, the administration of low-dose heparin was safe. Further trials including more patients and defined subgroups are needed before recommendations for the use of heparin in neutropenic sepsis can be made (CI).
Antithrombin has anti-thrombotic and anti-inflammatory properties. Based on the negative data from the KyberSept trial , a Cochrane analysis , and subgroup analyses of several trials [72, 87, 167], we do not recommend the routine use of antithrombin as treatment of neutropenic sepsis in the absence of disseminated intravascular coagulation (DIC; DI). However, in patients with DIC and sepsis, the administration of antithrombin may be considered (BII) .
Activated protein C (APC)
In response to the results of the PROWESS-SHOCK trial , APC is no longer in use.
Thrombomodulin decreases thrombus formation, activates protein C and has anti-inflammatory properties [2, 119, 148, 161]. Results from a phase IIb study suggested efficacy in patients with sepsis and suspected DIC . However, safety and efficacy is not known in cytopenic patients, and no evidence-based recommendation can be made.
Cytokines and haematopoietic growth factors (G-CSF, GM-CSF)
The central role of cytokines during the hyper- and anti-inflammatory phases of sepsis prompted clinical studies on the use of cytokines and cytokine inhibitors as therapeutic agents. However, studies on the therapeutic efficacy of IL-1 receptor antagonist, TNF-inhibitors, TLR-4 inhibitors and interferon gamma did not show a clinical benefit (EI) [52, 53, 117, 121, 139].
The known effect of G-CSF and GM-CSF in increasing the number of circulating granulocytes was the rationale for clinical studies assessing their role as additional therapy to antibiotics in febrile patients with chemotherapy-induced neutropenia. A meta-analysis of 13 randomized controlled trials including a total of 1,518 patients showed that G-CSF/GM-CSF effectively reduces the time to neutrophil recovery and the length of hospitalization . However, despite a marginally significant benefit for the use of G-CSF/GM-CSF in reducing infection-related mortality, overall mortality appeared not to be influenced. Even though this meta-analysis reported only mild side effects associated with G-CSF/GM-CSF treatment (bone pain, joint pain and flue-like symptoms), there is an accumulating number of publications on respiratory deterioration with ARDS during G-CSF/GM-CSF-induced neutropenia recovery [17, 18, 83, 147]. In non-neutropenic patients with pneumonia or sepsis, G-CSF/GM-CSF appeared to be safe but ineffective in reducing mortality rates or complications from infection [141, 169]. On the basis of the current studies and reports, we do not recommend the routine additional use of G-CSF or GM-CSF to standard treatment of sepsis in neutropenia (DI). Although GM-CSF seems to be able to reverse sepsis-induced immune paralysis, it is currently not available for treatment in the EU [110, 143].
The treatment of sepsis in neutropenia with i.v. immunoglobulin’s (IVIG) did not show a significant difference in survival in a randomized controlled trial . A meta-analysis on trials of IVIG in patients with sepsis identified 20 trials eligible for evaluation . Compared with placebo or no intervention, the use of polyclonal IVIG was associated with a survival benefit (relative risk 0.74). The number needed to treat to save one life was nine. Interestingly, more severely ill patients, those receiving treatment for more than 2 days and those receiving ≥1 g/kg, seemed to benefit most. As most of the individual trials analyzed had flaws in design, were rather small or performed during a time when the standard of care for septic patients was different from today; the authors conclude that a large randomized controlled trial should be performed . Three additional meta-analyses investigated the use of IVIG during sepsis and had similar outcomes [90, 94, 151]. In conclusion, there is moderate degree of evidence to support the use of IVIG in sepsis (BII).
Several case reports and phase I/II studies have shown some efficacy of granulocyte transfusions in patients with infections during severe neutropenia including patients with invasive fungal infections. However, complications have been reported as well, e.g. fatal CMV infection, allo-immunization and the transfusion-related acute lung injury syndrome. Recently, a randomized controlled trial has been published . It failed to show any beneficial effect, but it was small, and the authors discussed several problems associated with the design of the trial. A meta-analysis of the use of granulocyte transfusion in neutropenic neonates yielded equivocal results . Taken together, at this time, no recommendation can be given on the use of granulocyte transfusions outside of clinical trials.
Transfusion management in sepsis
The recommendations for substituting platelets or packed red blood cell in neutropenic patients can be applied to those patients developing sepsis as well. However, the cutoff for substitution is often set to higher values (platelets 20,000/μL instead of 10,000/μL; BIII). A randomized trial in children with sepsis showed no difference in outcome between a liberal (<9.5 g/dL) and a restrictive (<7 g/dL) trigger for erythrocyte transfusion . Although there are no prospective randomized studies available, we recommend a transfusion trigger of <9 g/dL haemoglobin level to optimize tissue oxygenation (there was no consensus inside the panel of experts regarding the strength of recommendation) .
Summary of recommendations
Summary of treatment recommendations given by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO)
Initial treatment with meropenem or with imipenem/cilastatin or with piperacillin/tazobactam
A combination treatment with an aminoglycoside in neutropenic patients with septic shock and severe sepsis may be considered
Albumin-containing solutions may be used in patients with sepsis and septic shock
The drug of choice to elevate the vasotonus is norepinephrine
In case of sepsis-related myocardial depression leading to low cardiac output despite adequate volume substitution, vasopressor treatment with dobutamine should be instituted
Treatment of pulmonary failure
Non-invasive positive pressure ventilation (CPAP or bilevel positive airway pressure) should be preferred if possible in patients without hypotension or altered mental status
An early start of non-invasive ventilation, prior to development of severe hypoxaemia, is favourable
Management of renal dysfunction
Intermittent haemodialysis and continuous renal replacement therapies are equivalent
No firm recommendations can be given for the use of increased doses of renal replacement therapy
Low-dose dopamine for protection of renal function is not recommended
Nutrition and control of metabolic functions
Enteral nutrition is preferred over parenteral nutrition
During initial phase of sepsis, energy supply should not exceed 20–25 kcal/kg ideal bodyweight (IBW)
During recovery, 25–30 kcal/kg IBW should be provided
We do not recommend general use of arginine, omega-3 fatty acids and combined formulations in patients with severe sepsis and septic shock
Glutamine substitution cannot be recommended in patients with severe sepsis and septic shock
Further clinical trials regarding the adequate dosing and treatment duration are needed before treatment with selenium can be recommended
Aiming at strictly normal blood glucose level of 4.4–6.6 mmol/L (80–120 mg/dL) is not recommended
Blood glucose levels should be kept ≤9.9 mmol/L (≤180 mg/dL) in septic neutropenic patients
A high variability of blood glucose levels in septic patients should be avoided, as this is associated with increased mortality
High-dose corticosteroids should not be used in neutropenic or non-neutropenic septic patients
The routine use of substitutive doses of hydrocortisone in neutropenic patients with sepsis is not recommended
Low-dose corticoid treatment may be considered in patients with insufficient restoration of blood pressure levels despite adequate fluid resuscitation and vasopressor treatment
Treatment with coagulation inhibitors
Further trials on the use of low-dose heparin (500 IU/h for 7 days) are needed before recommendations can be made
Routine use of antithrombin is not recommended as treatment of sepsis in neutropenic patients antithrombin may be considered during DIC and sepsis
Growth factors and immunoglobulins
The routine additional use of G-CSF or GM-CSF as standard treatment of sepsis in neutropenia is not recommended
There is moderate degree of evidence to support the use of i.v. immunoglobulins in sepsis
The cut-off for substitution of platelets is often set to a higher value (platelets 20,000/μL instead of 10,000/μL during sepsis)
A transfusion trigger of <9 g/dL haemoglobin during neutropenic sepsis is recommended
The AGIHO received no sponsoring for the preparation of these guidelines. Travel expenses were covered by the German Society of Hematology and Medical Oncology.
Olaf Penack: research funding—Bio Rad, Fresenius biotech, Gentium, Genzyme, Gilead.
Pierre Fabre: consultant—MSD; lecture honoraria/travel grants—Astellas, Gilead, Pfizer, MSD.
Carolin Becker: Travel Grants: Gilead Dieter Buchheidt: research funding—Gilead Sciences, Pfizer; consultant—Gilead Sciences; lecture honoraria/travel grants—Astellas, Gilead Sciences, MSD, Pfizer.
Michael Kiehl: consultant—Gilead, MSD, Roche, Janssen; lecture honoraria/travel grants—Gilead, MSD, Roche, Merck, Cellgene.
Marie von Lilienfeld-Toal: research funding—MSD, Gilead, Pfizer; consultant—MSD; lecture honoraria/travel grants—MSD, Astellas, Gilead, Janssen Cilag.
Marcus Hentrich: consultant—Takeda; lecture honoraria/travel grants—Gilead, MSD, Pfizer.
Marc Reinwald: research funding—Gilead, Pfizer; honoraria/travel grants—Astellas, MSD, Roche, Celgene.
Martin Schmidt-Hieber: lecture honoraria/travel grants—Gilead, Bristol Myers Squibb, MSD.
Thomas Weber: consultant—MSD; lecture honoraria/travel grants—Astellas.
Conflict of interest
All remaining authors have declared no conflicts of interest.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.